Rankings / Muscle & Strength

Sermorelin

Muscle & Strength · GHRH(1-29) analog

Tier C+

Reviewed by Read Off Label · Last reviewed · How we grade

gh-axispeptidecompoundable
5.6 / 10
Tier C+
Ev 4.5 Bn 5 Sf 7

Bottom line

Read Off Label grades Sermorelin as C+ (5.6/10) based on weak-moderate evidence, med benefit magnitude, and a low-med-risk safety profile.

The most "physiologic" GH-axis intervention because it preserves pulsatile release and somatostatin feedback — the short half-life (~10 min) means the pituitary continues to follow its endogenous rhythm rather than being chronically activated.

Studied, labeled, or reported-use context: Typical biohacker anti-aging: 200-500 mcg subQ at bedtime; pediatric GHD diagnostic 1 mcg/kg single… — Originally FDA-approved (Geref, Serono 1997 for pediatric GHD diagnosis); commercially withdrawn 2008 (Serono cited economic — not safety — reasons); currently legally compoundable from 503A/503B pharmacies in the US — SURVIVED the April 22 2026 FDA 503A Category 2 actions that removed 12 other peptides including dihexa; not individualized guidance.

Frontier potential — editorial judgment, not evidence

This is a separate axis from the grade above. It asks a different question: if this worked in humans, how much would it matter? It is our judgment, it is not part of the composite score, and it cannot raise a grade. A high number here is a statement about the idea, not about whether it works or whether anyone should take it.

4/10
Mechanistic story only Approved elsewhere

What the ceiling rests on

The best-characterised GHRH analogue, previously FDA-approved for paediatric GH deficiency — so unlike most peptides in this space it has a real regulatory and safety file behind it.

Why it may not get there

The approval was for diagnosed deficiency in children, which says little about healthy adults seeking enhancement. It was withdrawn from the US market for commercial rather than safety reasons, and the healthy-adult use has no controlled outcome data. The GH-longevity relationship points the wrong way.

What would change this A controlled adult trial with a functional rather than hormonal endpoint.

What the evidence says

The most "physiologic" GH-axis intervention because it preserves pulsatile release and somatostatin feedback — the short half-life (~10 min) means the pituitary continues to follow its endogenous rhythm rather than being chronically activated. Geref (Serono) was withdrawn 2008 for commercial reasons after the small pediatric-GHD market couldn't sustain manufacturing — FDA explicitly confirmed the withdrawal was NOT for safety or efficacy concerns. Remains the most-prescribed GHRH analog in compounding-pharmacy peptide protocols and is legally compoundable as of the April 2026 FDA 503A Category 2 update (sermorelin was NOT among the 12 peptides removed). **Clinical evidence**: the canonical aging trial remains Vittone 1997 — modest but real lean mass and IGF-1 effects after 16 weeks. No new major RCTs in 2024-2026 — the evidence base is thin and old. **Trend in practice**: increasingly displaced by CJC-1295 + ipamorelin combo stacks in compounding-clinic protocols because the dual-pathway combo produces larger measurable effects (at the cost of flattening the physiological pulse with the DAC variant, or requiring multiple daily injections without DAC). Sermorelin is used in protocols seeking pulsatile GH-axis stimulation; direct comparative clinical outcome evidence against CJC combinations is absent. **Product-characterization caveat**: 503A and 503B pharmacy products are regulated differently from poorly characterized gray-market "sermorelin" sold through research-chemical channels. **Sport context**: not specifically named on the WADA Prohibited List but GHRH analogs as a class fall under WADA S2 (peptide hormones).

Mechanism

N-terminal 29-amino-acid fragment of endogenous GHRH; native receptor agonist at GHRH-R; very short half-life (~10 min) — preserves physiological GH pulsatility and somatostatin feedback; binds the same pituitary receptor as endogenous GHRH so the release pattern remains pulsatile rather than tonic (contrast: CJC-1295 with DAC flattens the pulse over multi-day exposure)

Studied, labeled, or reported dose & route

Typical biohacker anti-aging: 200-500 mcg subQ at bedtime; pediatric GHD diagnostic 1 mcg/kg single IV/SC

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Sermorelin's effects?
Read Off Label rates the evidence for Sermorelin as Weak-Moderate and the benefit magnitude as med, producing an overall grade of C+ (5.6/10). The most "physiologic" GH-axis intervention because it preserves pulsatile release and somatostatin feedback — the short half-life (~10 min) means the pituitary continues to follow its endogenous rhythm rather than being chronically activated.
What safety findings are reported for Sermorelin?
Sermorelin has a low-med risk profile in the database. Low-Med (injection site reactions most common; preservation of physiological feedback minimizes HPA disruption; no measurable cortisol or prolactin elevation; theoretical insulin resistance at chronic supraphysiological exposure) Legal status: Originally FDA-approved (Geref, Serono 1997 for pediatric GHD diagnosis); commercially withdrawn 2008 (Serono cited economic — not safety — reasons); currently legally compoundable from 503A/503B pharmacies in the US — SURVIVED the April 22 2026 FDA 503A Category 2 actions that removed 12 other peptides including dihexa.
What doses or routes are reported for Sermorelin?
Typical biohacker anti-aging: 200-500 mcg subQ at bedtime; pediatric GHD diagnostic 1 mcg/kg single IV/SC This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Sermorelin work?
N-terminal 29-amino-acid fragment of endogenous GHRH; native receptor agonist at GHRH-R; very short half-life (~10 min) — preserves physiological GH pulsatility and somatostatin feedback; binds the same pituitary receptor as endogenous GHRH so the release pattern remains pulsatile rather than tonic (contrast: CJC-1295 with DAC flattens the pulse over multi-day exposure)

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.